Innovent Biologics Inc

📅 Upcoming

🕒 Recent(90d)

News

• RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
  Plus news about Avere Therapeutics, Novo Nordisk, Sobi, Innate Pharma, Oculis, Innovent Biologics and Daiichi Sankyo. 🌏 BeOne gets rights to RevMed drugs in 'select Asian markets': The deal includ…
  endpoints · 1d ago
• Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
  Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
  biospace · 16d ago
• J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
  J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
  biopharma_dive · 27d ago
• In latest deal, Innovent seeds Spero's future beyond GSK-owned antibiotic
  After partnering with four of the largest pharmaceutical companies over the past 18 months, Innovent Biologics is turning to a smaller partner for its next bet. An autoimmune drug candidate from th…
  endpoints · 29d ago
• These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
  Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.
  biopharma_dive · 1mo ago
• At BIO, tension over China biotech deal regulation looms
  Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.
  biopharma_dive · 1mo ago
• Innovent declares Phase 3 success for ADC that attracted huge Takeda deal
  Innovent Biologics' ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the success are still under wraps. The Phase 3 win will…
  endpoints · 2mo ago
• Otsuka showcases kidney drug data; Pfizer cuts an AI deal
  Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off gen…
  biopharma_dive · 2mo ago
• House bill aims to crack down on China biotech deals
  A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.
  biopharma_dive · 2mo ago
• STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
  Pharma updates from the Pharmalot campus via the Pharmalittle newsletter
  stat · 2mo ago